AstraZeneca targets 2024 growth but mixed views hit sharesIn almost a decade since AstraZeneca fended off a takeover by U.S. rival Pfizer, CEO Pascal Soriot has rebuilt the Anglo-Swedish drugmaker'...
AstraZeneca starts to make modest profit from Covid-19 vaccineThe Anglo-Swedish company's third-quarter results showed the vaccine contributed one cent to core earnings per share of $1.08, a rise of 14...
AstraZeneca says on track to deliver on Covid shots as sales hit $275 mnWhen including production and distribution from partners such as the Serum Institute of India, more than 300 million doses have been suppli...
AstraZeneca says diabetes drug Farxiga fails in COVID-19 studyThe British drugmaker said the drug did not achieve statistical significance in cutting the risk of the disease worsening and death in such...
Natco launches cut-price copies of AstraZeneca's patented anti-diabetes drugThe launch gives Natco an entry in the rapidly growing SGLT-2 segment that has mostly been dominated by global drug makers. However, for ro...
Alembic Pharma gets tentative nod from USFDA for glycemic control drugQuoting IQVIA sales data, the company said, Dapagliflozin Tablets, have an estimated market size of USD 1.7 billion for 12 months, ending D...